Healthcare
Suzuken Co., Ltd.(SZUKF)
Live Price
Offline$30.30
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
- Market Cap
- $376.66B
- Revenue Growth
- +0.6%
- EPS Growth
- +27.0%
- Dividend Yield
- 1.8%
Coverage: 253 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Suzuken Co., Ltd. (SZUKF) is a Healthcare stock with a market cap of $376.66B and listed on OTC. The stock last traded around $30.30 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of +27.0%, a dividend yield of 1.8%. What stands out right now is revenue +0.6%, EPS +27.0%, free cash flow -217.0% with operating margin 1.4% and ROIC 5.5%. The dividend is present but secondary, with a yield around 1.8%. Valuation is more restrained than many high-expectation growth names at P/E 11.0 and price/sales 0.2. Stock Foundry combines SZUKF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.6% vs +7.6% peer median
Operating Margin
Below sector median
+1.4% vs +19.4% peer median
P/E
Below sector median
11.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +0.6% and EPS at +27.0%, with operating margin around 1.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.8%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SZUKF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SZUKF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SZUKF and SPY.
Company Overview
Suzuken Co., Ltd.
Other OTC
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
- Leadership
- Shigeru Asano
- IPO Date
- Sep 10, 2013
- Employees
- 13.1k
- Street Address
- 8 Higashi Kataha-machi
- Mailing
- Nagoya, 461-8701
- Region
- Nagoya, JP
- Reporting Currency
- USD
- Investor Line
- 81 52 961 2331
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 11.0
- EV/EBITDA
- 4.3
- Price/Sales
- 0.2
- Price/Book
- 0.9
Growth
- Revenue
- +0.6%
- EPS
- +27.0%
- Free Cash Flow
- -217.0%
Profitability
- Gross Margin
- 7.8%
- Operating Margin
- 1.4%
- Net Margin
- 1.4%
- ROE
- 8.6%
- ROIC
- 5.5%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 1.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.